Cerus Blood Safety Trial Meets Goal
Cerus Corp announced that its late stage study showed red blood cells treated with its blood safety technology performed as well as conventional cells. The trial met its primary goal with no significant difference in adverse events.
Xurve View
Insights:
Xurve View
Cerus Corp reported that its blood-safety system met the primary endpoint in a late-stage clinical trial on Monday afternoon. The technology showed non-inferiority to conventional red blood cell transfusions in patients. The findings mark a key regulatory milestone for the pathogen-reduction platform.
